1. Stocks
  2. Gland Pharma Ltd.
  3. Swot
Gland Pharma Ltd. SWOT Analysis: Strengths, Weakness, Opportunity, and Threats
Stocks where Mutual Funds Increased Holdings in Past Month
Rising Net Cash Flow and Cash from Operating activity 375.3% returns for Nifty 500 over 5.9 years
Effectively using its capital to generate profit - RoCE improving in last 2 years -16.8% returns for Nifty 500 over 1.9 years
Effectively using Shareholders fund - Return on equity (ROE) improving since last 2 year
Efficient in managing Assets to generate Profits - ROA improving since last 2 year
Company with Low Debt
Company able to generate Net Cash - Improving Net Cash Flow for last 2 years
Annual Net Profits improving for last 2 years
Company with Zero Promoter Pledge
Near 52 Week High
MFs increased their shareholding last quarter
Companies with growing costs YoY for long term projects
Bearish Stocks - Stocks with Medium to Low Trendlyne Momentum Score 86.4% returns for Nifty 500 over 4.5 years
Promoter decreasing their shareholding
Rising Delivery Percentage Compared to Prev Day
Companies with Upcoming Results
Results Screener: Stocks with upcoming results which are seeing positive shifts in share price
RSI indicating price strength
Stocks near 52 Week High with Significant Volumes
Stocks with Expensive Valuations according to the Trendlyne Valuation Score 177.2% returns for Nifty 500 over 4.5 years
Stocks with high PE (PE > 40)
Stocks gaining versus previous close, open price and RSI
Top Gainers